Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis
Prostate cancer (PCa) is the most common cancer in men worldwide. The current gold standard for diagnosing PCa relies on a transrectal ultrasound-guided systematic core needle biopsy indicated after detection changes in a digital rectal examination (DRE) and elevated prostate-specific antigen (PSA)...
Main Authors: | Milena Matuszczak, Jack A. Schalken, Maciej Salagierski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/13/3373 |
Similar Items
-
Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis
by: Wieke C. H. Visser, et al.
Published: (2020-12-01) -
Emerging Role of Exosomes in Liquid Biopsy for Monitoring Prostate Cancer Invasion and Metastasis
by: Zhengfan Gao, et al.
Published: (2021-05-01) -
Liquid Biopsy Potential Biomarkers in Prostate Cancer
by: Jochen Neuhaus, et al.
Published: (2018-09-01) -
Glycans as Biomarkers in Prostate Cancer
by: Emma Scott, et al.
Published: (2019-03-01) -
Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers
by: Milena Matuszczak, et al.
Published: (2020-05-01)